en
Scientific article
English

Targeting chemokine receptors in HIV: a status report

Published inAnnual review of pharmacology and toxicology, vol. 48, p. 425-461
Publication date2008
Abstract

Since the identification of CCR5 and CXCR4 as HIV coreceptors a little over a decade ago, there has been hope that coreceptor inhibitors will be able to make an impact on the HIV epidemic, both as novel therapeutic drugs and as agents used in prevention. Significant progress has been made in the understanding of how coreceptor choice might impact HIV pathology and how coreceptor blockade may affect health. In this review, we focus on some of the key issues that are emerging now that CCR5 has been validated as a promising target for HIV prevention strategies and at a time when a CCR5 inhibitor has been approved in the United States as the first in a new class of anti-HIV therapeutic drugs.

Keywords
  • Anti-HIV Agents/pharmacology
  • Drug Delivery Systems
  • Drug Resistance, Viral/physiology
  • HIV Infections/drug therapy/prevention & control
  • HIV-1/drug effects/metabolism
  • Humans
  • Receptors, CCR5/antagonists & inhibitors/metabolism
  • Receptors, CXCR4/antagonists & inhibitors/metabolism
Research group
Citation (ISO format)
KUHMANN, Shawn E., HARTLEY, Oliver. Targeting chemokine receptors in HIV: a status report. In: Annual review of pharmacology and toxicology, 2008, vol. 48, p. 425–461. doi: 10.1146/annurev.pharmtox.48.113006.094847
Main files (1)
Article (Accepted version)
accessLevelRestricted
Identifiers
ISSN of the journal0362-1642
515views
0downloads

Technical informations

Creation06/18/2009 12:25:00 PM
First validation06/18/2009 12:25:00 PM
Update time03/14/2023 3:08:58 PM
Status update03/14/2023 3:08:58 PM
Last indexation01/15/2024 6:35:35 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack